Cogent Hits Mark In Phase III GIST Trial Of Bezuclastinib

 
• By Alaric DeArment
  
Cancer cells on scientific background.3d illustration
Cogent reported positive results from its Phase III PEAK study of bezuclastinib in GIST. • Source: Shutterstock
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Clinical Trials

More from R&D